Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Subcutaneous Bortezomib, Cyclophosphamide and Rituximab (BCR) Versus Fludarabine, Cyclophosphamide and Rituximab (FCR) for Initial Therapy of Waldenstrőm's Macroglobulinaemia (WM): a Randomized Phase II Trial

NCT01592981 is registered in ClinicalTrials.gov with University College, London as lead sponsor.

NCT NCT01592981
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01592981 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Subcutaneous Bortezomib, Cyclophosphamide and Rituximab (BCR) Versus Fludarabine, Cyclophosphamide and Rituximab (FCR) for Initial Therapy of Waldenstrőm's Macroglobulinaemia (WM): a Randomized Phase II Trial
Lead sponsor
University College, London
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2013
Completion date
August 2, 2020
Enrollment
60 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

waldenstrom's macroglobulinaemia